Mast Cell Chymase and Kidney Disease. 2020

Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
Centre de Recherche sur l'inflammation, CNRS ERL8252, Faculté de Médecine site Bichat, Université de Paris, Inserm UMR1149, 16 rue Henri Huchard, F-75018 Paris, France.

A sizable part (~2%) of the human genome encodes for proteases. They are involved in many physiological processes, such as development, reproduction and inflammation, but also play a role in pathology. Mast cells (MC) contain a variety of MC specific proteases, the expression of which may differ between various MC subtypes. Amongst these proteases, chymase represents up to 25% of the total proteins in the MC and is released from cytoplasmic granules upon activation. Once secreted, it cleaves the targets in the local tissue environment, but may also act in lymph nodes infiltrated by MC, or systemically, when reaching the circulation during an inflammatory response. MC have been recognized as important components in the development of kidney disease. Based on this observation, MC chymase has gained interest following the discovery that it contributes to the angiotensin-converting enzyme's independent generation of angiotensin II, an important inflammatory mediator in the development of kidney disease. Hence, progress regarding its role has been made based on studies using inhibitors but also on mice deficient in MC protease 4 (mMCP-4), the functional murine counterpart of human chymase. In this review, we discuss the role and actions of chymase in kidney disease. While initially believed to contribute to pathogenesis, the accumulated data favor a more subtle view, indicating that chymase may also have beneficial actions.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008407 Mast Cells Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR. Basophils, Tissue,Basophil, Tissue,Cell, Mast,Cells, Mast,Mast Cell,Tissue Basophil,Tissue Basophils
D009393 Nephritis Inflammation of any part of the KIDNEY. Nephritides
D004198 Disease Susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases. Diathesis,Susceptibility, Disease,Diatheses,Disease Susceptibilities,Susceptibilities, Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015842 Serine Proteinase Inhibitors Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. Serine Endopeptidase Inhibitor,Serine Endopeptidase Inhibitors,Serine Protease Inhibitor,Serine Protease Inhibitors,Serine Proteinase Antagonist,Serine Proteinase Antagonists,Serine Proteinase Inhibitor,Serine Proteinase Inhibitors, Endogenous,Serine Proteinase Inhibitors, Exogenous,Serine Protease Inhibitors, Endogenous,Serine Protease Inhibitors, Exogenous,Antagonist, Serine Proteinase,Endopeptidase Inhibitor, Serine,Inhibitor, Serine Endopeptidase,Inhibitor, Serine Protease,Inhibitor, Serine Proteinase,Protease Inhibitor, Serine,Proteinase Antagonist, Serine,Proteinase Inhibitor, Serine
D053818 Chymases A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation. Chymase,Chymase-1,Chymotrypsin-Like Protease,Chymotrypsin-Like Proteases,Chymase 1,Chymotrypsin Like Protease,Chymotrypsin Like Proteases

Related Publications

Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
October 2019, Histochemistry and cell biology,
Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
February 2012, Current hypertension reviews,
Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
February 2002, Biochemical and biophysical research communications,
Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
August 2019, The British journal of dermatology,
Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
January 1991, Annals of the New York Academy of Sciences,
Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
January 1999, Thorax,
Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
March 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
April 2001, Kidney international,
Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
May 1990, Biochemistry,
Shamila Vibhushan, and Manuela Bratti, and Juan Eduardo Montero-Hernández, and Alaa El Ghoneimi, and Marc Benhamou, and Nicolas Charles, and Eric Daugas, and Ulrich Blank
June 2016, The Journal of dermatology,
Copied contents to your clipboard!